A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Fludarabine
- Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Hodgkin's disease; Leukaemia; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2017 Planned End Date changed from 1 Sep 2014 to 1 Oct 2018.
- 31 Oct 2013 Planned end date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.